Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)

The optimal combination of bevacizumab with cytotoxic or cytostatic drugs in recurrent glioblastoma is unknown. We performed a phase 2 trial of combined bevacizumab and fotemustine for patients with glioblastoma at first relapse after radiotherapy and temozolomide. The primary endpoint was 6-month p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Soffietti, Riccardo, Trevisan, Elisa, Bertero, Luca, Cassoni, Paola, Morra, Isabella, Fabrini, Maria Grazia, Pasqualetti, Francesco, Lolli, Ivan, Castiglione, Anna, Ciccone, Giovannino, Rudà, Roberta
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer US 2013
Schlagworte:
Clinical Study
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3905193/
https://ncbi.nlm.nih.gov/pubmed/24293233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-013-1317-x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge